Latest news
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH - MoomooMoomoo · Mon, 03 Aug 2026 14:15:52 GMTAltimmune begins phase 3 trial of pemvidutide for MASH - Investing.comInvesting.com · Mon, 03 Aug 2026 13:09:04 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 12:00:00 GMTAltimmune (ALT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALT - MarketBeatMarketBeat · Mon, 03 Aug 2026 07:00:00 GMTAltimmune alcohol use disorder drug hits the mark in phase 2 - pharmaphorumpharmaphorum · Wed, 29 Jul 2026 10:15:54 GMTAltimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder - pharma.economictimes.indiatimes.compharma.economictimes.indiatimes.com · Wed, 29 Jul 2026 07:24:04 GMTAltimmune trial win for pemvidutide in alcohol use disorder - The Pharma LetterThe Pharma Letter · Wed, 29 Jul 2026 07:00:00 GMTAltimmune's GLP-1 drug could help reduce heavy drinking linked to alcohol use disorder - FirstWord PHARMAFirstWord PHARMA · Tue, 28 Jul 2026 22:25:16 GMT